Jessica Tyrus Mackay
Download vCard

Working in a world-renowned research lab taught Jessica the challenges that face researchers when developing novel biotech products; working for the U.S. District Court gave her a real-world taste of the issues patent holders and defendants face in the courtroom. As a partner at Green, Griffith & Borg-Breen, she applies these insights to guide clients to the best possible strategies for protecting their intellectual property and growing their businesses.

Jessica represents plaintiffs and defendants in all facets of patent litigation and consultation arising under the Hatch‐Waxman Act, from initial opinions through trial and appeal. She has served as trial counsel in patent infringement litigation in the U.S. federal district courts and as appellate counsel before the Federal Circuit. She also advises clients on freedom‐to‐operate, due diligence, trademark and trade dress issues, and has represented patentees before the Patent Trial and Appeal Board in inter partes review (IPR) proceedings.

“Green Griffith has a collaborative environment, and we bring that spirit to client engagements as well,” Jessica says. “I want my clients to be successful; my role is to help them be successful. We have frank discussions, listen carefully and then tailor our involvement and recommendations to their priorities. We’re going to give you our honest opinion rather than pursue litigation for litigation’s sake.”

In all her work, Jessica focuses on delivering long-term value and building enduring relationships with her clients.

Before joining Green Griffith, Jessica was an associate at Leydig, Voit & Mayer, Ltd. She also served as a judicial extern for the Hon. Martin C. Ashman, U.S. Magistrate Judge for the Northern District of Illinois, and worked as a laboratory intern at Argonne National Laboratory.


Chicago-Kent College of Law, J.D., with high honors
         Chicago-Kent Law Review, “Notes and Comments” editor
         Chicago-Kent Journal of Intellectual Property, associate editor
         Order of the Coif, member
         Moot Court Honor Society
Benedictine University, B.S., chemistry, summa cum laude

Professional Affiliations
  • Chicago Bar Association
  • Intellectual Property Owners Association (IPO)
  • Chicago Women in IP
  • Coalition of Women’s Initiatives in Law
  • Intellectual Property Law Association of Chicago
Court Admissions
  • U.S. District Court for the Northern District of Illinois
  • U.S. Court of Appeals for the Federal Circuit
  • Registered Patent Attorney, U.S. Patent and Trademark Office, No. 64,742
  • Listed in Intellectual Asset Management’s (IAM) Patent 1000 in Litigation, 2021
  • Named in the Illinois Rising Stars list, as published in Illinois Super Lawyers, 2016-2021
  • Selected by peers as a Leading Lawyer in Intellectual Property Law and Patent Law – Leading Lawyers Network, 2015-2021
Representative Matters
  • Boehringer Ingelheim et al. v. Aurobindo Pharma Ltd., 20-00023-IMK (N.D. W. Va.) (linagliptin – Tradjenta®)
  • Adapt Pharma et al. and Opiant Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., et al., 16-7721-JLL-JAD, 17-00864, -02877, -05100, 18-05752, -09880 (D.N.J.) (naloxone hydrochloride ‐ Narcan®)
  • Adapt Pharma et al. and Opiant Pharmaceuticals, Inc. v. Perrigo UK Finco Limited Partnership, 18-15287 (D.N.J.) (naloxone hydrochloride ‐ Narcan®)
  • Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc., IPR2019-00685, -00686, -00687, -00688, -00689, -00690, -00691, -00692, -00693, -00694, -00695, -00696, -00697, -00698, and -00699 (naloxone hydrochloride ‐ Narcan®)
  • Horizon Medicines LLC v. Teva Pharmaceuticals USA, Inc., 20-08188-SRC-CLW (D.N.J.) (famotidine/ibuprofen – Duexis®)
  • Horizon Medicines LLC v. Alkem Laboratories Ltd.,18‐01014‐LPS (D. Del.) (famotidine/ibuprofen – Duexis®)
  • Dexcel Pharma Technologies Ltd. et al. v. Apotex Corp. et al., 17‐2423‐SDW (D.N.J.) (Omeprazole DR Tablets, 20 mg (OTC))
  • Dexcel Pharma Technologies Ltd. et al. v. Dr. Reddy’s Labs., Ltd. et al., 15‐8042‐SDW (D.N.J.) (Omeprazole DR Tablets, 20 mg (OTC))
  • Dexcel Pharma Technologies Ltd. et al. v. Sun Pharma Global FZE et al., 15‐8017‐SDW (D.N.J.) (Omeprazole DR Tablets, 20 mg (OTC))
  • Horizon Pharma Ireland Limited, et al. v. Watson Laboratories, Inc., 14‐7992‐NLH (D.N.J.) (diclofenac sodium topical ‐ Pennsaid® 2%)
  • Horizon Pharma Ireland Limited, et al. v. Lupin Ltd., 15‐3051‐NLH (D.N.J.) (diclofenac sodium topical ‐ Pennsaid® 2%)
  • Horizon Therapeutics, Inc. v. Par Pharmaceutical, Inc., 14‐384‐JRG‐RSP (E.D. Tex) (glycerolphenylbutyrate ‐ Ravicti®)
  • Horizon Pharma Inc., et al. v. Par Pharmaceutical Cos., Inc., et al., 13‐102‐LPS (D. Del.) (famotidine/ibuprofen ‐ Duexis®)
  • Helsinn Healthcare SA, et al. v. Cipla Ltd., et al., 14‐427‐GMS (D. Del.) (palonosetron HCl injection ‐ Aloxi®)
  • Pfizer Inc. v. Lupin Ltd., 12-811-SLR (D. Del.) (O-desmethylvenlafaxine succinate – Pristiq®)
  • Warner Chilcott Co., LLC v. Lupin Ltd., et al., 11‐5048‐JAP (D.N.J.) (norethindrone acetate/ethinyl estradiol – Lo Loestrin® Fe)
  • Warner Chilcott Co., LLC v. Lupin Ltd., et al., 11‐7228 (D.N.J.) (norethindone/ethinyl estradiol ‐ Generess® Fe)
  • AstraZeneca AG et al. v. Lupin Ltd., et al., 11‐4275‐JAP (D.N.J.) (naproxen/esomeprazole ‐ Vimovo®)
  • In re Fenofibrate Patent Litigation, 11-md-JSR (S.D.N.Y.) (fenofibrate – Antara®)
  • Shire Canada Inc. et al. v. Natco Pharma Ltd., 09‐3165‐JDG (S.D.N.Y.) (lanthanum carbonate ‐ Fosrenol®)

Powerful advice. Persuasive advocacy.